US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

38.06

+0.18000.48%

Volume:114.36K

Turnover:4.36M

Market Cap:256.91M

PE:- -

High:38.28

Open:38.22

Low:38.01

Close:37.88

52wk High:41.49

52wk Low:22.33

Shares:6.75M

Float Shares:6.75M

Volume Ratio:0.62

T/O Rate:1.69%

Dividend:0.28

Dividend Rate:0.74%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Evotec initiates clinical trial evaluating JST-018

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Moderately bullish activity in Moderna with shares down 1.79%

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send?

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Ascletis Starts U.S. Phase I Trial of Oral Obesity Drug ASC36

Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial

MediciNova to Participate in Two Investor Conferences in September

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

Press Release: Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend

Upstream Bio presents results from VALIANT trial at ERS Congress

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

The Second Act of Biotech

Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones Top Company Headlines at 9 am ET: EQT to Buy Insurance Broker McGill in $2 Billion Deal | Tesla-Challenging ...

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/IDNA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":38.06,"timestamp":1789156800000,"preClose":37.88,"halted":0,"volume":114363,"delay":0,"changeRate":0.004751847940865884,"floatShares":6750000,"shares":6750000,"eps":0,"marketStatus":"Pre-Mkt","change":0.18,"latestTime":"09-14 05:55:56 EDT","open":38.22,"high":38.28,"low":38.005,"amount":4356036.121553999,"amplitude":0.00726,"askPrice":43.56,"askSize":100,"bidPrice":34.56,"bidSize":3,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789392600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":38.06,"sharesOutstanding":5100000,"nav":37.991633,"aum":258343104.4,"dividendRate":0.007399,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.06,"preClose":38.06,"latestTime":"19:30 EDT","volume":20,"amount":761.1742,"timestamp":1789169407146,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6184424703621776,"impliedVol":0.1978,"impliedVolPercentile":0.516},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6184424703621776,"shares":6750000,"dividePrice":0.2816,"high":38.28,"amplitude":0.00726,"preClose":37.88,"low":38.005,"week52Low":22.33,"pbRate":"--","week52High":41.49,"institutionHeld":0,"latestPrice":38.06,"committee":-0.941748,"eps":0,"divideRate":0.007399,"volume":114363,"delay":0,"ttmEps":0,"open":38.22,"prevYearClose":26.19,"prevWeekClose":38.06,"prevMonthClose":39.26,"prevQuarterClose":33.75,"fiveDayClose":40.29,"twentyDayClose":35.24,"sixtyDayClose":29.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666558799","title":"Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666558799?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358479/0/en/satellos-announces-forazapadin-as-assigned-international-nonproprietary-name-for-lead-drug-candidate-sat-3247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","BMED","SAT","BK4181","BK4218","DBB","INN","GDOC","IDNA","NVIB","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589922","title":"Evotec initiates clinical trial evaluating JST-018","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666589922?lang=en_us&edition=fundamental","pubTime":"2026-09-09 17:15","pubTimestamp":1788945324,"startTime":"0","endTime":"0","summary":"Evotec (EVO) announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVO","MEDX","GDOC","HYLG","BK4121","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNTL","IBBQ","BIB","RSPH","JHMH","GNMX","PBPH","IEIH","IBRN","NVIB","APXH","AZNH","LLYX","HYLG","IBB","HRTS","CURE","SURI","CNCR","PJP","BBP","JDOC","PTH","MDTX","IBBJ","FTXH","WDNA","PBE","GSKH","SBIO","FBT","MEDI","BBH","GNOM","LFSC","MRNY","GDOC","FHLC","CANC","PSCH","TBXU","GPCR","SYNB","FXH","IDNA","BME","MEDX","XPH","PINK","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372326","title":"Moderately bullish activity in Moderna with shares down 1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372326?lang=en_us&edition=fundamental","pubTime":"2026-09-09 02:20","pubTimestamp":1788891611,"startTime":"0","endTime":"0","summary":"Moderately bullish activity in Moderna (MRNA), with shares down $2.60 near $142.95. Options volume relatively light with 44k contracts traded and c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-down-1-79-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-down-1-79-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4548","IDNA","LGHT","BK4139","MRNA","BK4532","BK4551","WDNA","BK4534","BK4568","GNOM","BK4533","BK4585","MRNY","BK4501","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372878","title":"Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send?","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372878","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372878?lang=en_us&edition=fundamental","pubTime":"2026-09-09 02:15","pubTimestamp":1788891334,"startTime":"0","endTime":"0","summary":"• Vertex shares faced volatility and profit-taking after rallying near their 52-week high.\n• The Crinetics acquisition integration will not be non-GAAP accretive until 2029.\n• Technical indicators show a neutral MACD, neutral RSI, and oversold Williams %R.","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262156625-market-movers-vrtx-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2456880835.USD","SG9999001176.USD","BIB","LU1035775433.USD","LU0058720904.USD","LU0234570918.USD","IE0009355771.USD","BK4533","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU2417539215.USD","LU0109394709.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","IE00B19Z9Z06.USD","LU1093756168.USD","VRTX","BK4567","LU2089984988.USD","LU2236285917.USD","LU1430594728.SGD","LU2237438978.USD","BK4532","LU0432979614.USD","BK4139","LU1674673691.USD","LU2362540622.SGD","LU0823416689.USD","BK4585","TBXU","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2468319806.SGD","PBE","LU2462157665.USD","LU0256863811.USD","SGXZ57979304.SGD","IE00BZ9MQY76.HKD","IDNA","LU0320765992.SGD","LU1674673428.USD","SG9999013999.USD","IBBQ","BK4588","GNMX","LU0289739699.SGD","IE00B19Z3581.USD","LU2362541273.HKD","LU2362541513.USD","LU0061475181.USD","IE00B19Z9P08.USD","LU0417517546.SGD","LU1778281490.HKD","SG9999001176.SGD","LU2324357040.USD","IE0002270589.USD","LU0079474960.USD","LU1585245621.USD","IBB","IE00B894F039.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","LU1093756325.SGD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","SBIO","GSKH","FHLC","IBBQ","BME","MDTX","RSPH","LLYX","CNCR","CURE","PBE","PJP","JDOC","IBBJ","BIB","CANC","LFSC","SYNB","FTXH","JHMH","PTH","IBRN","BBH","GPCR","TBXU","WDNA","PBPH","NVIB","HYLG","PSCH","SURI","PSIL","IBB","MEDI","BBP","FBT","PINK","FXH","MEDX","MNTL","HRTS","XPH","AZNH","GNMX","APXH","LENZ","GDOC","GNOM","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378444","title":"PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378444","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378444?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:30","pubTimestamp":1788870600,"startTime":"0","endTime":"0","summary":"Dr. Soon-Shiong will Join PDS Biotech’s Board of Directors PDS Biotech Plans toProgressDevelopment of PDS0301ImmunocytokineinSolidTumors PRINCETON, N.J., Sept.  08, 2026 (GLOBE NEWSWIRE) -- PDS Biotec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357657/37149/en/pds-biotech-announces-up-to-22-55-million-financing-led-by-dr-patrick-soon-shiong-founder-of-nantworks.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4585","XBI","BK4124","BK4113","IDNA","BK4581","BK4202","MSS","BK4588","PATK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732264","title":"Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732264","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732264?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:01","pubTimestamp":1788865260,"startTime":"0","endTime":"0","summary":"Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical developmentAppointment strengthens executive leadership team as Editas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYNB","BK4585","WDNA","BK4556","ASCI","IDNA","GNMX","EDIT","IE00B19Z4B17.USD","BK4139","BK4588","HELX","BK4214","IE00B66KJ199.SGD","IE00B7SZL793.SGD","AAP","IE0031619046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321700","title":"Ascletis Starts U.S. Phase I Trial of Oral Obesity Drug ASC36","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321700?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:08","pubTimestamp":1788862087,"startTime":"0","endTime":"0","summary":"Ascletis Pharma, Inc. ( ($HK:1672) ) has issued an announcement. Ascletis Pharma Inc. has initiated a Phase I clinical trial in the U.S. for ASC36 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascletis-starts-u-s-phase-i-trial-of-oral-obesity-drug-asc36?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascletis-starts-u-s-phase-i-trial-of-oral-obesity-drug-asc36?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","MEDX","NVIB","IDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665703321","title":"Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665703321","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665703321?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:05","pubTimestamp":1788861944,"startTime":"0","endTime":"0","summary":"Roivant announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-announces-positive-results-from-phase-2-phocus-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-announces-positive-results-from-phase-2-phocus-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","GDOC","HYLG","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665601324","title":"MediciNova to Participate in Two Investor Conferences in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2665601324","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665601324?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., Sept.  08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchang","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357430/7767/en/medicinova-to-participate-in-two-investor-conferences-in-september.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710400.SGD","LU1074936037.SGD","LU1989772923.USD","BK4504","MEDX","LU2264538146.SGD","MNOV","LU2133065610.SGD","BK4534","LU2487616109.SGD","LU0267386448.USD","BMED","BK4127","LU2347655156.SGD","LU1989772840.SGD","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU0795875169.SGD","IE00BKVL7J92.USD","LU0912757837.SGD","LU0234570918.USD","LU0390134368.USD","LU0971096721.USD","LU2028103732.USD","LU2111349929.HKD","NVIB","GDOC","LU0098860793.USD","LU1732799900.SGD","LU0106831901.USD","LU2089283258.USD","LU1548497426.USD","LU1791710582.SGD","LU0528227936.USD","IE00B3S45H60.SGD","BK4585","LU1064131342.USD","IAI","LU2089284900.SGD","BK4139","IDNA","LU0210528500.USD","LU1720051108.HKD","LU0557290698.USD","HYLG","KBWB","LU0053666078.USD","LU0006306889.USD","BK4516","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665432460","title":"Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665432460","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665432460?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","BK4611","LU1861558580.USD","LU1878469433.USD","BK4585","BK4535","BK4556","ALT","LENZ","LU1861559042.SGD","BK4139","IDNA","BK4007","EPV","BK4588","BK4505","BK4539","BK4599","PRTO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321351","title":"Press Release: Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321351?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"BEIJING, Sept. 8, 2026 /PRNewswire/ -- Waterdrop Inc.  , a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced its unaudited financial results for the three and six months ended June 30, 2026 and a cash dividend.Financial and Operational Highlights for the Second Quarter of 2026-- Strong Core Business Growth: Net operating revenue for the second quarter. rose to RMB1,448.2 million , representing a robust. year-over-year increase of 72.8%. Insurance-related income for the. quarter reached RMB1,333.2 million , up 80.5% from the. -- Improved Operating Performance: In the second quarter of 2026, operating","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIX","CHAT","HYLG","IDNA","VTHR","WDH","MEDX","GDOC","ARTY","BK4509","QTOC","BK4173","BK4539","NVIB","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326159","title":"Upstream Bio presents results from VALIANT trial at ERS Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326159?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:10","pubTimestamp":1788858619,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) presented results from the Phase 2 VALIANT clinical trial evaluating the safety and efficacy of verekitug in adults with severe ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-presents-results-from-valiant-trial-at-ers-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-presents-results-from-valiant-trial-at-ers-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB","NVIB","MEDX","IDNA","GDOC","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665157325","title":"Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665157325","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665157325?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:30","pubTimestamp":1788852600,"startTime":"0","endTime":"0","summary":"– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357341/0/en/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-the-treatment-of-severe-asthma-in-oral-presentation-at-ers-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","TSLY","GDOC","ELOL","TSLR","TSDD","CRSH","NVIB","TSLS","TSL","09366","TSLQ","TSLW","TSLI","TEST","TSLL","TSLG","TESL","TESC","TSLT","09766","07366","TSII","HYLG","TSYY","TSLZ","TSLP","TSLO","IDNA","07766","TLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665531933","title":"The Second Act of Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2665531933","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665531933?lang=en_us&edition=fundamental","pubTime":"2026-09-07 19:08","pubTimestamp":1788779310,"startTime":"0","endTime":"0","summary":"Pfizer sells dopamine. Moderna made the COVID vaccine. Both are betting their next decade on medicines that barely existed when their stocks peaked...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-second-act-of-biotech?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-second-act-of-biotech?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BLSP4239.USD","SGXZ57979304.SGD","LU0985481810.HKD","BK4581","LU1894683348.USD","LU0225771236.USD","IE00B3T34201.USD","LU0289739699.SGD","BK4585","BK4548","LU0306807586.USD","BK4533","SG9999001176.USD","SG9999003800.SGD","MRNX","BK4588","IE00B19Z3B42.SGD","MRNA","BK4501","IE0002270589.USD","LU0321505439.SGD","LU2596442595.SGD","LU0122379950.USD","BK4007","LU0868494617.USD","BK4568","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU1883839398.USD","LU0234572021.USD","MRNY","PFE","WDNA","BK4599","BK4532","OZEM","SG9999002224.SGD","BK4592","SG9999013999.USD","GNOM","SG9999001176.SGD","LU0306806265.USD","LU0456855351.SGD","IE00BBT3K403.USD","BK4534","LU1066051498.USD","BK4551","LU1894683264.USD","LU1066053197.SGD","BK4139","LU0058720904.USD","LU0170899867.USD","LGHT","SG9999002232.USD","LU1057294990.SGD","IDNA","IE000M9KFDE8.USD","BK4550","LU0225284248.USD","SG9999011175.SGD","LU1023059063.AUD","LU0321505868.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665682593","title":"Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2665682593","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665682593?lang=en_us&edition=fundamental","pubTime":"2026-09-05 17:01","pubTimestamp":1788598891,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($ACRS) ), ( ($EYPT) ), ( ($VRTX) ), ( ($GTLB) ) and ( ($NB) ). Here is a breakdown of their recent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/aclaris-eyepoint-vertex-gitlab-niocorp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/aclaris-eyepoint-vertex-gitlab-niocorp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z9Z06.USD","LU1093756168.USD","LU0079474960.USD","LU0757428866.USD","LU2236285917.USD","LU2468319806.SGD","SG9999001176.SGD","LU1778281490.HKD","BIB","IE0009355771.USD","LU2417539215.USD","LU1559883803.SGD","LU2089984988.USD","EYPT","LU0289739699.SGD","PBE","IE0002270589.USD","LU1674673428.USD","LU2456880835.USD","SG9999013999.USD","LU2362541513.USD","BBH","IE0002141913.USD","IE00BFTCPJ56.SGD","GNMX","LU0234570918.USD","LU1093756325.SGD","LU0417517546.SGD","TBXU","IE00B4R5TH58.HKD","IDNA","IBB","IE00BJJMRZ35.SGD","VRTX","LU1035775433.USD","LU1069344957.HKD","BK4533","IE00B894F039.SGD","LU2462157665.USD","IE00BZ9MQY76.HKD","GTLB","VERX","BK4607","BK4097","IE00B19Z9P08.USD","LU2324357040.USD","IE00B19Z3B42.SGD","IE00B2B36J28.USD","IBBQ","BK4613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354019","title":"Guardant announces FDA approval of Guardant360 CDx as companion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354019","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354019?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:15","pubTimestamp":1788560112,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patien...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","TBXU","XLVX","BK4585","EKG","PSCH","LU0889565916.HKD","IBB","GNOM","BK4551","NVIB","LU0320765992.SGD","FRTY","IEIH","BK4588","PTH","IDNA","PINK","LABU","LFSC","FFOX","GH","HELX","SYNB","BMED","TECB","MRNY","MEDI","BK4535","BK4196","GNMX","BBP","LU0109394709.USD","RSPH","GDOC","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665351836","title":"Healthcare Stocks Pick up Steam as Investors Play Offense and Defense","url":"https://stock-news.laohu8.com/highlight/detail?id=2665351836","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665351836?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:22","pubTimestamp":1788553320,"startTime":"0","endTime":"0","summary":"Want a prescription for investing success?","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014906.USD","LLII","LU0466842654.USD","LU0889565916.HKD","LU2552382132.HKD","LU0354030438.USD","LU0456855351.SGD","LU0345770993.USD","LU0122379950.USD","XLV","LU0061475181.USD","LU1868837300.USD","LU0256863811.USD","LU1232071149.USD","LU1291159041.SGD","LU0058720904.USD","LU2112291526.USD","LU2168564065.EUR","SG9999001176.USD","IHF","LU0109391861.USD","LU2468319806.SGD","PJP","THNR","LU2237438978.USD","LU1974910355.USD","LU0823434740.USD","IBB","SGXZ31699556.SGD","LU0006306889.USD","LU1093756325.SGD","LU0158827781.USD","LU2168564495.EUR","SG9999014880.SGD","LU1023059063.AUD","LU0683600562.USD","LU0820561909.HKD","LU2237443622.USD","LU0114720955.EUR","LU0345770308.USD","LU1983299246.USD","LU0689472784.USD","LU2063271972.USD","LU0094547139.USD","LU0708995401.HKD","LU0823434583.USD","LU0882574139.USD","LU1127390331.HKD","LU2746668974.SGD","LU2023250330.USD","IE00B1BXHZ80.USD","LU2264538146.SGD","LU2089283258.USD","LU2237443465.HKD","LU2602419157.SGD","LU2168564222.USD","SG9999013999.USD","IE00BN29S564.USD","LU1035775433.USD","LU0079474960.USD","LU0238689110.USD","IE0009355771.USD","LU0787776722.HKD","SG9999001176.SGD","IE0004445015.USD","LU1280957306.USD","LU0882574055.USD","LU2491050071.SGD","LU2491050154.USD","IE0004445239.USD","LU1868836757.USD","LLYZ","LU2357305700.SGD","LU2471134952.CNY","MHIP","LU0786609619.USD","ELIS","LU0672654240.SGD","LU1988902786.USD","BK4532","LU0109394709.USD","LU2471134523.USD","XBI","IDNA","IE00BK4W5M84.HKD","IE00B4R5TH58.HKD","BK4007","SG9999015945.SGD","LU0417517546.SGD","LU0640476718.USD","LU1814569148.SGD","BK4533","IE0005OL40V9.USD","OZEM","FHLC","LABU","LU1069344957.HKD","LU1989771016.USD","LU1323610961.USD","IE00B7KXQ091.USD","LU1691799644.USD","LU1551013342.USD","LU2552382058.USD","LU0316494557.USD","LU2236285917.USD","LU2271345857.HKD","IE00B775H168.HKD","LU2237443978.SGD","LU2361044865.SGD","IE00BFTCPJ56.SGD","LU0174119429.USD","IE00BJLML261.HKD","SGXZ99366536.SGD","LU0823416689.USD","IE00BJJMRX11.SGD","LU1868836914.USD","SGXZ51526630.SGD","LU2089284900.SGD","IE00BFSS7M15.SGD","LU2213496289.HKD","SG9999015978.USD","IE00BJJMRY28.SGD","LU2896262040.SGD","MRNY","MEDI","BK4501","SGXZ81514606.USD","LU1868837136.USD","ILDR","LU2237443895.HKD","GDOC","IE00BK4W5L77.USD","LU1093756168.USD","SG9999017495.SGD","LU0133085943.USD","HRTS","LU0203202063.USD","LU1804176565.USD","LU0097036916.USD","LU2108987350.USD","LU2237443549.SGD","IE00B4JS1V06.HKD","JDOC","LU1366192091.USD","LU2361044949.HKD","LU2750360997.AUD","RXL","SG9999014898.SGD","GB00BDT5M118.USD","LU2168563687.JPY","LU2211815571.USD","LU2324357040.USD","LU0820562030.AUD","LU2089984988.USD","LU0354030511.USD","LU2028103732.USD","LLYX","LU0234572021.USD","LU0320765992.SGD","LU2462157665.USD","LU2023250504.SGD","LGHT","LU0158827948.USD","LU0266013472.USD","LU0432979614.USD","BK4581","LU1629891620.HKD","LU2023251221.USD","LU2111349929.HKD","SG9999018857.SGD","TRUH","BK4568","PPH","IE0002141913.USD","IHE","BK4548","LU1720051108.HKD","MRNX","IE00BJJMRZ35.SGD","SG9999015952.SGD","IE00BKPKM429.USD","BK4139","IE00BFSS8Q28.SGD","LU2756315318.SGD","SGXZ57979304.SGD","LU2461242641.AUD","LU2750360641.GBP","LU0353189763.USD","LU2237443382.USD","TMED","LU0820561818.USD","LU0385154629.USD","MRNA","LU2552382215.SGD","LU1064131342.USD","LU2746668461.USD","IE00BJT1NW94.SGD","LU2456880835.USD","BK4534","BK4585","LU0198837287.USD","LU2168564149.EUR","MEDX","SG9999014914.USD","LU2491049909.HKD","GNOM","LU0943347566.SGD","LU2106854487.HKD","LU2361045086.USD","LU0106261372.USD","LU2417539215.USD","IE00BKDWB100.SGD","LU2756315664.SGD","LU1145028129.USD","LU1720051017.SGD","LLY","BK4588","LU1057294990.SGD","LU0353189680.USD","LU1712237335.SGD","LU0096364046.USD","LU0210536198.USD","LU2471134879.HKD","BK4551","LU0203201768.USD","LU0289739699.SGD","LU0320765059.SGD","LU0471298694.HKD","LU1061106388.HKD","LU0471298777.SGD","BK4516","FTXH","CANC","LU1548497426.USD","LU0323591593.USD","LU0256863902.USD","LU1868836591.USD","WDNA","AGNG","IE00BWXC8680.SGD","LU1267930730.SGD","LU2087625088.SGD","LU1979441026.SGD","SG9999018865.SGD","LU1551013425.SGD","LU0964807845.USD","SG9999015986.USD","LU2462591350.SGD","IE00B1XK9C88.USD","IE0001KFT4U8.USD","IE00B2B36J28.USD","LU1623119135.USD","LU2265009873.SGD","LU1917777945.USD","LU0225283273.USD","LU2360106947.USD","BK4599","LU2471134796.USD","ELIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664033473","title":"Dow Jones Top Company Headlines at 9 am ET: EQT to Buy Insurance Broker McGill in $2 Billion Deal | Tesla-Challenging ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2664033473","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664033473?lang=en_us&edition=fundamental","pubTime":"2026-09-04 21:00","pubTimestamp":1788526800,"startTime":"0","endTime":"0","summary":"EQT to Buy Insurance Broker McGill in $2 Billion DealEQT has agreed to buy a majority stake in insurance broker McGill and Partners for $2 billion, the Swedish investment group said.----Tesla-Challeng","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLG","LU2210150020.SGD","LU0957808578.USD","LU0256863902.USD","LU2357125470.USD","FAI","LU1951198990.SGD","LU1720051108.HKD","LU0708994859.HKD","LU2237438978.USD","LU2271345857.HKD","LU2491049909.HKD","SG9999014898.SGD","LU0345770993.USD","SG9999017495.SGD","LU0353189763.USD","LU1064131342.USD","IE00BKVL7J92.USD","NVDS","AGOX","LU1645745479.HKD","LU2361044949.HKD","LU2237957811.SGD","LU0289739343.SGD","LU2087621335.USD","BK4608","LU0238689110.USD","BK4007","LU1988902786.USD","SG9999001424.SGD","LU0133085943.USD","LU1917777945.USD","EFIV","WANT","LU0234570918.USD","LU0494093205.USD","LU1989772840.SGD","IE0004091025.USD","LU0124676726.USD","LU1153585028.USD","RXL","LU1244550221.USD","LU1670756490.USD","LU3102509885.SGD","LU0642271901.SGD","LU2462157665.USD","IE00BK4W5L77.USD","GAMR","SG9999002224.SGD","IE0004445239.USD","IE0004445015.USD","LU1823568750.SGD","SGXZ51526630.SGD","LU1202635105.USD","BK4551","THMR","LU0316494557.USD","LU0738911758.USD","LU0274383776.USD","LU2265009873.SGD","LU1267930730.SGD","LU2756315664.SGD","LU0096364046.USD","07766","LU1316542783.SGD","LU2065171402.SGD","LU1116320901.HKD","LU0889565833.HKD","WATS","BK4532","CLSE","LU0106261372.USD","LU1923622291.USD","TTEQ","LU2089985449.USD","LU1267930813.SGD","LU2125154935.USD","LU0289960550.SGD","IE00B1XK9C88.USD","LU2592432038.USD","IE0034235295.USD","IE00BFSS7M15.SGD","IE00B4JS1V06.HKD","LU1934455863.HKD","IE0001KFT4U8.USD","LU1839511570.USD","IE000ITXATA3.USD","SMH","BK4548","LU0082616367.USD","LU0787776722.HKD","IE00BJJMRX11.SGD","LU2210149790.SGD","LU2023250843.SGD","LU0081259029.USD","LU2106854487.HKD","ESUM","LU0210536198.USD","LU1585245621.USD","LU2237443549.SGD","LU0265550359.USD","LU2065169927.USD","BK4585","LU1429558221.USD","LU0912757837.SGD","LU2236285917.USD","LU1267930573.SGD","TSLW","LU0203202063.USD","LU0006306889.USD","LIT","FDTX","3NVD.UK","LU2168564065.EUR","SHOC","LU1127390331.HKD","LU2543165471.USD","ARTY","LU2458330169.SGD","LU2213496289.HKD","HK0000914660.USD","LU0345768740.USD","LU0080751232.USD","LU1861215975.USD","BK4605","SG9999015978.USD","LU2471134879.HKD","LU0323239441.USD","LU2092937148.SGD","IE00BDCRKT87.USD","LU1732799900.SGD","IE000M9KFDE8.USD","IE00BHPRN162.USD","IE000YTNTUN2.SGD","LU0158827948.USD","TSLT","IE00BQXX3C00.GBP","LU2168564222.USD","LU1430594728.SGD","LU1791710400.SGD","LU0965508806.USD","IE000W1ABFV2.USD","LU0965509283.SGD","LU2360032135.SGD","WISE","LU2931357623.SGD","IE000Q6AESB8.SGD","LU0345774391.USD","LU0077335932.USD","HK0000320223.HKD","LU1046421795.USD","LU2381873111.SGD","LU1084165304.USD","SGXZ31699556.SGD","LU0203201768.USD","IE00BFSS8Q28.SGD","LU2413666426.HKD","ADBG","LU1037948897.HKD","LU2552382058.USD","LU0211328371.USD","LU1989764748.USD","LU0208291251.USD","BK4554","LU0823411888.USD","LU0708995401.HKD","BK4528","CHAT","LU0094547139.USD","LU1551013425.SGD","LU0820561909.HKD","NVDU","BK4529","LFGY","LU0345769128.USD","NVD","LU0154236417.USD","LU1280957306.USD","LU2317271919.USD","MRNX","DIPS","LU0109392836.USD","LU1815333072.USD","LU2023250330.USD","LU2111349929.HKD","LU0795875169.SGD","LU1066051225.USD","LU1267930490.SGD","LU1037948541.HKD","LU0868494617.USD","LU2602419157.SGD","LU0528227936.USD","TRUH","LU2249611893.SGD","LU1093756325.SGD","SNPE","LU0170899867.USD","LU2125909593.SGD","BK4141","LU2125154778.USD","LU2095319765.USD","LU0672654240.SGD","IE00BJTD4V19.USD","LU0985320562.USD","LU1935042991.SGD","LU0198837287.USD","LU1162221912.USD","SPTE","LU0096362180.USD","LU0211331839.USD","LU1244550494.USD","NVII","IE00BN8TJ469.HKD","LU0069063385.USD","TSLR","LU2247934214.USD","JDOC","IE00BMPRXR70.SGD","LU1941712264.USD","LU2750360997.AUD","FDRV","IE00B4R5TH58.HKD","IE00BK4W5M84.HKD","CMAG","LU0122379950.USD","LU2237443895.HKD","HK0000320264.USD","LU2360107168.USD","NVD3.UK","IE00BWXC8680.SGD","LU0511384066.AUD","LU1066051498.USD","IE0009355771.USD","LU2471134523.USD","SG9999014880.SGD","LU2089284900.SGD","IETC","LU2347655156.SGD","LU2896262040.SGD","LU0726765562.USD","LU1983260115.SGD","BK4567","LU0109391861.USD","LU1974910355.USD","HK0000304797.USD","TESL","IE00B4YYXB79.USD","BK4534","LU0215105999.USD","METV","LU0965509101.SGD","NVDG","LU0820561818.USD","GDOC","LU1032466523.USD","LU0011850046.USD","WDNA","LGHT","LU0719512351.SGD","IE00BLSP4239.USD","LU1979441026.SGD","TSLP","LU2272731600.USD","LU2461242641.AUD","LU2463028550.USD","LU0061474960.USD","LU0949170772.SGD","SG9999015945.SGD","LU1023059063.AUD","XLK","LU2471134952.CNY","IE00BQXX3D17.EUR","BK4543","IE00BKPKM429.USD","SG9999000418.SGD","BK4023","BK4501","IE00B5TLWC47.USD","LU1951200564.SGD","LU2272731782.SGD","BK4604","SG9999018865.SGD","LU0965509010.AUD","BK4099","LU2324357040.USD","SG9999004303.SGD","IYH","BK4566","LU0210528500.USD","SG9999015986.USD","XLV","LU1366333091.USD","LU2125909759.SGD","LU1435385759.SGD","LU1291159041.SGD","LU0788109477.HKD","TSYY","USXF","LU1642822529.SGD","IE00BD6J9T35.USD","LU2637965513.SGD","LU0792757196.USD","LU0823416689.USD","ADBU","IE0004086264.USD","LU0310800379.SGD","LU2357305700.SGD","LU0980610538.SGD","LU1791710582.SGD","LU0210533765.USD","IE00B7KXQ091.USD","LU0557290698.USD","LU0689626769.HKD","LU1066053197.SGD","LU0143551892.USD","NVDO","BK4549","SOXX","LU1732800096.USD","LU1778281490.HKD","BK4614","LU1814569148.SGD","IE00BFTCPJ56.SGD","LU0203347892.USD","TRFK","IE00BQXX3F31.USD","LU1242518931.SGD","LU0444973449.USD","LU2491050071.SGD","LU2756315318.SGD","LU2237443465.HKD","LU2413666699.HKD","LU2290526834.HKD","TSL","LU0256863811.USD","LU1261432733.SGD","CRSH","NVDS.UK","LU0345769631.USD","BK4527","BK4598","LU1935042215.USD","NULC","IE0002141913.USD","IE00B775SV38.USD","IE00BBT3K403.USD","LU1989772923.USD","LU0345768153.USD","LU2092627202.USD","LU0320765059.SGD","SGXZ81514606.USD","IE00B19Z8W00.USD","LU0048584097.USD","LU1119994496.HKD","LU0056508442.USD","LU1992135472.HKD","LU1721428933.USD","TSII","LU0477156953.USD","LU2286300806.USD","LU1941712348.USD","SG9999015952.SGD","LU1821325948.USD","LU2148611432.USD","LU2750360641.GBP","LU0323240290.USD","09388","LU0444971666.USD","IXJ","LU0130517989.USD","MRK","LU0354030511.USD","LU0061475181.USD","TSLI","LU2237443978.SGD","IE00BJT1NW94.SGD","LU0979878070.USD","09788","LU0353189680.USD","LU1571399168.USD","NVIW.SI","TSLA","IE0034235188.USD","LU2063271972.USD","LU1718418525.SGD","LU1923623000.USD","LU2100268510.USD","LU2168564149.EUR","IE000KEQY171.SGD","LU1232071149.USD","IE00BJJMRZ35.SGD","LU1989771016.USD","LU0289961442.SGD","LU2357627491.SGD","LU0072462426.USD","LU1244550577.SGD","LU2065170008.USD","HK0000914686.HKD","IE00B5949003.HKD","LU1057294990.SGD","LU2458330243.SGD","IE0005OL40V9.USD","LU0266013472.USD","TSLY","LU0310799852.SGD","ESLG","LU1323610961.USD","LU1712237335.SGD","ANV","LU2322448791.USD","ILDR","LU1003077747.HKD","LU1366192091.USD","LU1880398554.USD","TLA","NVDQ","LU1868836757.USD","SG9999014914.USD","LU2237443622.USD","IDNA","LU0251132253.USD","LU1880398471.USD","IE0003U64NQ7.SGD","LU2294711713.HKD","LU1061106388.HKD","LU1035773651.USD","LU0314104364.USD","NVDY","PPH","LU1720051017.SGD","VGT","IE00B19Z9505.USD","IE0034235303.USD","2NVD.UK","STSLAmain","LU2250418816.HKD","IXN","TEK","SG9999001176.SGD","BK4581","SG9999014542.SGD","07788","LU0138981039.USD","NVDX","IE00BKDWB100.SGD","LU1992135399.USD","LU2505996681.GBP","LU1066051811.HKD","LU2108987350.USD","LU1804176565.USD","LU0234572021.USD","LU1674673691.USD","LU1861558580.USD","LU0345774631.USD","LU2433249047.HKD","VHT","IE00BSNM7G36.USD","LU2023250504.SGD","LU2237957902.USD","LU0689472784.USD","SGXZ57979304.SGD","AIFD","LU1803068979.SGD","IE00B1BXHZ80.USD","LU0061474705.USD","IE00BLSP4452.SGD","IE0009G5SDU7.USD","LU2133065610.SGD","07388","LU1201861249.SGD","LU0320765489.SGD","LU1400636574.HKD","IE00BZ199S13.USD","TTXU","LU2999663052.SGD","LU0265550946.USD","SG9999015341.SGD","LU1868836914.USD","LU2468319806.SGD","LU1983299246.USD","LU0098860793.USD","TSLL","LU2954938101.SGD","NVYY","LU0943347566.SGD","SG9999014559.SGD","LU1623119135.USD","LU1935043536.SGD","LU2430703178.SGD","LU0823414478.USD","LU2191332357.HKD","LU2360106780.USD","LU1868837136.USD","BK4503","BK4139","LU2361045086.USD","LU0289739699.SGD","LU0395794307.EUR","LU1035775433.USD","LU1674673428.USD","LU0323591593.USD","LU1116320737.USD","PAWZ","SG9999013999.USD","LU1923622614.USD","SG9999001440.SGD","LU1093756168.USD","HK0000532082.HKD","BK4579","LU1633808545.USD","LU2746668974.SGD","IE00B3S45H60.SGD","MRNA","LU0158827781.USD","LU1989764664.SGD","LU0107464264.USD","LU0348723411.USD","LU0889566641.SGD","LU1815336760.USD","LU1551013342.USD","IE00B775H168.HKD","LU2430703251.USD","TSLO","TSLS","LU0267386448.USD","LU1069347547.HKD","IE00BN29S564.USD","LU0029864427.USD","LU1496350502.SGD","LU2279689827.SGD","LU0466842654.USD","SGXZ99366536.SGD","SG9999014906.USD","LU0211327993.USD","LU0957791311.USD","CNEQ","LU1400636657.SGD","SOXQ","BK4612","HK0000306701.USD","LU0354030438.USD","LU2272731865.HKD","LU0417517546.SGD","HK0000819398.USD","IE00BFXG0V08.USD","LU2083900584.USD","IDRV","LU1691799644.USD","LU1861559042.SGD","LU1144417596.USD","LU1934455194.USD","IE00B19Z8X17.USD","LU2065171311.SGD","HK0000306685.HKD","SOXY","LU2264538146.SGD","BK4587","LU2125909916.SGD","LU0964807845.USD","LU1235294995.USD","LU2746668461.USD","LU0308772762.SGD","IE00B3M56506.USD","LU2211815571.USD","LU0823421333.USD","TSLQ","LU1934455277.USD","LU0345770308.USD","LU2023251221.USD","LU0683600562.USD","TEST","LU2506951792.HKD","SG9999018857.SGD","LU1699723380.USD","LU1868837300.USD","LU2168564495.EUR","LU2505996509.AUD","NVDB","TYLG","LU0868494708.USD","ELOL","LU2491050154.USD","LU0127658192.USD","LU1861220033.SGD","LU2394011477.USD","GB00BDT5M118.USD","IE00BMPRXN33.USD","LU1242518857.USD","VT","TSLZ","LU0820562030.AUD","SMHX","LU0786609619.USD","LU0157215616.USD","LU0097036916.USD","HRTS","LU0320765646.SGD","LU0859254822.USD","LU2089283258.USD","SG9999001176.USD","LU0724617625.USD","LU2473716301.USD","LU0187121727.USD","SG9999002232.USD","LU2462591277.SGD","LU0545039389.USD","LU2417539215.USD","LU1400636491.USD","AIPI","SG9999014575.USD","SG9999015358.SGD","IE00BYQQ9H92.USD","LU0070302665.USD","IE00BZ1G4Q59.USD","LU2552382215.SGD","LU0640476718.USD","LU1145028129.USD","BK4555","LU2077746001.SGD","SNVDAmain","GNOM","LU0432979614.USD","LU0861579265.USD","IE00BMPRXQ63.HKD","IE00BJJMRY28.SGD","LU2403377893.USD","NVD2.UK","FHLC","IE00BJLML261.HKD","LU2047632596.USD","BK4559","LU0174119429.USD","BK4516","FTEC","LU0053666078.USD","LU0070217475.USD","LU0390134368.USD","IE00B3SWFQ91.USD","ADBE","LU2112291526.USD","USD","LU2089984988.USD","FTXH","LU0882574139.USD","LU2456880835.USD","LU2242649171.HKD","LU0128525929.USD","BK4574","LU0057025933.USD","LU0472753341.HKD","LU1069344957.HKD","09766","IE00BJTD4N35.SGD","LU2471134796.USD","LU0130102774.USD","LU0276348264.USD","BK4568","LU1861127337.USD","ROM","LU2361044865.SGD","LU0347712357.USD","LU2097344357.USD","IE00BYXW3230.USD","LU2462591350.SGD","IE0009356076.USD","BMED","MRNY","LU1929549753.HKD","IE00B2B36J28.USD","ABFL","BK4533","LU1852331112.SGD","NVDD","LU0058720904.USD","LU2168563687.JPY","LU0342679015.USD","LU1548497426.USD","NVC","BK4511","SG9999014567.USD","LU2552382132.HKD","SNVD.UK","LU2322448957.HKD","09366","BK4550","CHPX","HK0000304805.HKD","NVDW","LU0203345920.USD","TSDD","LU1914381329.SGD","LU0175139822.USD","LU0553294199.USD","LU0823434740.USD","LU2087625088.SGD","LU2244417387.USD","TESC","LU1935043023.USD","LU2326559502.SGD","LU0823421416.USD","LU2237443382.USD","LU2420271590.USD","LU2347655073.USD","07366","SMOG","LU0795875086.SGD","LU2097344431.USD","LU2430703095.HKD","LU0823434583.USD","LU0225283273.USD","IE00BDRTCR15.USD","LU2452424414.USD","NVDL","LU0648001328.SGD","SGXZ80539844.SGD","LU1935042488.USD","LU0079474960.USD","LU2860962120.EUR","LU0942090050.USD","LU2028103732.USD","LU2054465674.USD","LU2487616109.SGD","LU0476273544.USD","LU2242650005.HKD","LU1629891620.HKD","BK4592","LU2125909247.SGD","SGXZ23171101.USD","LU0661504455.SGD","LU0823414551.USD","LU1496350171.SGD","LU1868836591.USD","NVDA","JGRO","BK4588","IHE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}